In vitro cytotoxicity and bioavailability of solid lipid nanoparticles containing tamoxifen citrate

Pharmaceutical Development and Technology

Volumn 19, Issue 7, 2014, Pages 824-832

  Hashem, Fahima M ^a   Nasr, Mohamed ^a   Khairy, Ahmed ^b  

^a Ein Helwan   (Egypt)

^b 6th of October   (Egypt)

Author keywords

Bioavailability; In vitro cytotoxicity; Solid lipid nanoparticles; Tamoxifen citrate

Indexed keywords

GLYCEROL STEARATE; POLOXAMER; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; STEARIC ACID; TAMOXIFEN CITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; LIPIDS; NANOPARTICLES; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN;

EID: 84898751208     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2013.836218     Document Type: Article

References (53)

1. Gao S, Singh J. In vitro percutaneous absorption enhancement of a lipophilic drug tamoxifen by terpenes. J Control Rel 1998;51: 193-199.
2. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18:3748-3757.
3. Cameron DA, Ritchie AA, Langdon S, et al. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedates tumour regression. Breast Cancer Res Treat 1997;45:99-107.
4. Chawla JS, Amiji MM. Cellular uptake and concentrations of tamoxifen upon administration in poly ("-caprolactone) nanoparticles. AAPS PharmSci 2003;5:E3.
5. Tukker JJ, Blankenstein MA, Nortier JW. Comparison of bioavailability in man of tamoxifen after oral and rectal administration. J Pharm Pharmacol 1986;38:888-892.
6. Bonferoni MC, Rossi S, Ferrari F, et al. Factorial analysis of the influence of dissolution medium on drug release from carrageenandiltiazem complexes. AAPS PharmSciTech 2000;1:E15.
7. Hardman J, Limbird L, Gilman A. The pharmacological basis of therapeutics. 10th ed. NewYork, USA: McGraw-Hill; 2006.
8. Shin SC, Choi JS, Li X. Enhanced bioavailability of tamoxifen after oral administration of tamoxifen with quercetin in rats. Int J Pharm 2006;313:144-149.
9. Chawla JS, Amiji MM. Biodegradable poly ("-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm. 2002;249:127-138.
10. Brigger I, Chaminade P, Marsaud V, et al. Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new antiestrogen formulation. Int J Pharm 2001;214:37-42.
11. Kapse SV, Gaikwad RV, Samad A, Devarajan PV. Self nanoprecipitating preconcentrate of tamoxifen citrate for enhanced bioavailability. Int J Pharm 2012;429:104-112.
12. Hu FX, Neoh KG, Kang ET. Synthesis and in vitro anti-cancer evaluation of tamoxifen-loaded magnetite/PLLA composite nanoparticles. Biomaterials 2006;27:5725-5733.
13. Memisoglu-Bilensoy E, Vural I, Bochot A, et al. Tamoxifen citrate loaded amphiphilic beta-cyclodextrin nanoparticles: in vitro characterization and cytotoxicity. J Control Rel 2005;104:489-496.
14. Martinez A, Muniz E, Iglesias I, et al. Enhanced preclinical efficacy of tamoxifen developed as alginate-cysteine/disulfide bond reduced albumin nanoparticles. Int J Pharm 2012;436:574-581.
15. Yang L, Geng Y, Li H, et al. Enhancement the oral bioavailability of praziquantel by incorporation into solid lipid nanoparticles. Pharmazie 2009;64:86-89.
16. Ugazio E, Cavalli R, Gasco MR. Incorporation of cyclosporin A in solid lipid nanoparticles (SLN). Int J Pharm 2002;241:341-344.
17. Li H, Zhao X, Ma Y, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Rel 2009;133:238-244.
18. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul 1999;16:205-213.
19. Song CX, Labhasetwar V, Murphy H, et al. Formulation and characterization of biodegradable nanoparticles for intravascular local drug delivery. J Control Rel 1997;43:197-212.
20. Kingsley JD, Dou H, Morehead J, et al. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 2006;1:340-350.
21. Wang W, Zhu R, Xie Q, et al. Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles. Int J Nanomedicine 2012;7:3667-3677.
22. Patel BD, Modi RV, Thakkar NA, et al. Development and characterization of solid lipid nanoparticles for enhancement of oral bioavailability of Raloxifene. J Pharm Bioallied Sci 2012;4: S14-16.
23. Neves AR, Lucio M, Martins S, et al. Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability. Int J Nanomedicine 2013;8:177-187.
24. Chalikwar SS, Belgamwar VS, Talele VR, et al. Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Colloids Surf B Biointerfaces 2012; 97:109-116.
25. Fontana G, Maniscalco L, Schillaci D, et al. Solid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activity. Drug Deliv 2005;12:385-392.
26. Barbieri S, Sonvico F, Como C, et al. Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: loading, enzymetrigger release and cell uptake. J Control Rel 2013;167:276-283.
27. Alhaj NA, Abdullah R, Ibrahim S, Bustamam A. Tamoxifen drug loading solid lipid nanoparticles prepared by hot high pressure homogenization techniques. Am J Pharmacol Toxicol 2008;3: 219-224.
28. Reddy LH, Vivek K, Bakshi N, Murthy RS. Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm Dev Technol 2006;11:167-177.
29. Schubert M, Muller-Goymann C. Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm 2003;55: 125-131.
30. Vitorino C, Carvalho FA, Almeida AJ, et al. The size of solid lipid nanoparticles: an interpretation from experimental design. Colloids Surf B Biointerfaces 2011;84:117-130.
31. Hu L, Tang X, Cui F. Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol 2004;56:1527-1535.
32. Ling G, Zhang P, Zhang W, et al. Development of novel selfassembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition. J Control Rel 2010;148:241-248.
33. Kheradmandnia S, Vasheghani-Farahani E, Nosrati M, Atyabi F. Preparation and characterization of ketoprofen-loaded solid lipid nanoparticles made from beeswax and carnauba wax. Nanomedicine 2010;6:753-759.
34. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-1112.
35. Merey HA, Galal MM, Salem MY, Abdel-Moety EM. Chromatographic determination of tamoxifen citrate in presence of some co-administered drugs. J Pharm Res 2011;4:2458-2461.
36. Manjunath K, Reddy JS, Venkateswarlu V. Solid lipid nanoparticles as drug delivery systems. Methods Find Exp Clin Pharmacol 2005; 27:127-144.
37. Leroux JC, Allemann E, Doelker E, Gurny R. New approach for the preparation of nanoparticles by an emulsification-diffusion method. Eur J Pharm Biopharm 1994;41:14-18.
38. Villalobos-Hernandez JR, Muller-Goymann CC. Novel nanoparticulate carrier system based on carnauba wax and decyl oleate for the dispersion of inorganic sunscreens in aqueous media. Eur J Pharm Biopharm 2005;60:113-122.
39. Pathan IB, Setty M. Enhancement of transdermal delivery of tamoxifen citrate using noanoemulsion vehicle. Int J Pharm Tech Res 2011;3:287-297.
40. Doktorovova S, Shegokar R, Rakovsky E, et al. Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies. Int J Pharm 2011;420:341-349.
41. Das S, Ng WK, Kanaujia P, et al. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: effects of process variables. Colloids Surf B Biointerfaces 2011;88:483-489.
42. Sari A, Akcay M, Soylak M, Onal A. Polymer-stearic acid blends as form-stable phase change material for thermal energy storage. J Sci Indi Res 2005;64:991-996.
43. Jagadeesh H, Deviv K. Tamoxifen loaded poly ("-caprolactone) based injectable microsphers for breast cancer. Int J Pharm Pharm Sci 2010;2:189-195.
44. Muller RH, Radtke M, Wissing SA. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 2002;242: 121-128.
45. Abbasalipourkabir R, Salehzadeh A, Abdullah R. Antitumor activity of tamoxifen loaded solid lipid nanoparticles on induced mammary tumor gland in Sprague-Dawley rats. Afr J Biotechnol 2010;9: 7337-7345.
46. Jain AK, Swarnakar NK, Godugu C, et al. The effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifen. Biomaterials 2011;32:503-515.
47. Priano L, Esposti D, Esposti R, et al. Solid lipid nanoparticles incorporating melatonin as new model for sustained oral and transdermal delivery systems. J Nanosci Nanotechnol 2007;7: 3596-3601.
48. Li H, Zhao X, Ma Y, et al. Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles. J Control Rel 2009;133:238-244.
49. Hunt JN, Knox MT. Control of gastric emptying. Am J Dig Dis 1968;13:372-375.
50. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv Drug Deliv Rev 1998;34:135-154.
51. John H, Charlotte J, Jonathan A, et al. Controlled vaccine release in the gut-associated lymphoid tissue, I: orally administered biodegradable microspheres target the Peyer's patches. J Control Rel 1990;11: 205-214.
52. Bargoni A, Cavalli R, Caputo O, et al. Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 1998;15:745-750.
53. Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 1998;87: 164-169.